silatrane and Hepatitis-B

silatrane has been researched along with Hepatitis-B* in 1 studies

Other Studies

1 other study(ies) available for silatrane and Hepatitis-B

Article	Year
Synthesis and biological evaluation of nucleoside analogues than contain silatrane on the basis of the structure of acyclovir (ACV) as novel inhibitors of hepatitis B virus (HBV). Bioorganic & medicinal chemistry letters, 2013, Mar-01, Volume: 23, Issue:5 Hepatitis B virus (HBV) infection causes major public health problems worldwide. Acyclovir (ACV) is mainly used to inhibit herpes simplex virus (HSV) rather than HBV. In this study, we used the combination principle to design and synthesize nucleoside analogues that contain silatrane on the basis of the structure of ACV. We found that the compounds were effective inhibitors of HBV, both in vitro and in vivo. All of the compounds showed suppressive activity on the expression of HBV surface antigen (HBsAg) and HBV e antigen (HBeAg) in the HepG2.2.15 cell line with low cytotoxicity. One of compounds was studied in HBV transgenic mice model, and the test results showed its ability to reduce the levels of HBsAg, HBeAg and HBV DNA by ELASE and qPCR. Furthermore, significant improvement of T lymphocyte was observed after treatment, as evaluated by flow cytometry (FCM). Topics: Acyclovir; Animals; Antiviral Agents; Bridged Bicyclo Compounds, Heterocyclic; Female; Hep G2 Cells; Hepatitis B; Hepatitis B virus; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Organosilicon Compounds; Purine Nucleosides; Random Allocation	2013

Article

Year

Synthesis and biological evaluation of nucleoside analogues than contain silatrane on the basis of the structure of acyclovir (ACV) as novel inhibitors of hepatitis B virus (HBV).

Bioorganic & medicinal chemistry letters, 2013, Mar-01, Volume: 23, Issue:5

Hepatitis B virus (HBV) infection causes major public health problems worldwide. Acyclovir (ACV) is mainly used to inhibit herpes simplex virus (HSV) rather than HBV. In this study, we used the combination principle to design and synthesize nucleoside analogues that contain silatrane on the basis of the structure of ACV. We found that the compounds were effective inhibitors of HBV, both in vitro and in vivo. All of the compounds showed suppressive activity on the expression of HBV surface antigen (HBsAg) and HBV e antigen (HBeAg) in the HepG2.2.15 cell line with low cytotoxicity. One of compounds was studied in HBV transgenic mice model, and the test results showed its ability to reduce the levels of HBsAg, HBeAg and HBV DNA by ELASE and qPCR. Furthermore, significant improvement of T lymphocyte was observed after treatment, as evaluated by flow cytometry (FCM).

Topics: Acyclovir; Animals; Antiviral Agents; Bridged Bicyclo Compounds, Heterocyclic; Female; Hep G2 Cells; Hepatitis B; Hepatitis B virus; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Organosilicon Compounds; Purine Nucleosides; Random Allocation

2013